US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Oncology Pharma Inc
(OP:
ONPH
)
0.0500
+0.0200 (+66.67%)
Delayed Quote
Updated: 3:56 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncology Pharma Inc
World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly
↗
March 23, 2024
Prosecutors push for harshest punishment for Sam Bankman-Fried, convicted on fraud charges in FTX collapse. Defense seeks leniency.
Via
Benzinga
Topics
Fraud
Lawsuit
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
July 12, 2022
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
June 29, 2022
SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
June 08, 2022
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
May 09, 2022
SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc. Originally,...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
April 13, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Reports on Progress with Ribera Solutions
March 02, 2022
SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions'...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
February 23, 2022
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Expands on Feasibility Studies and Data
February 17, 2022
SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
February 14, 2022
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
February 08, 2022
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma's New Year Update
January 10, 2022
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year. The Company has...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Meeting Towards Future Developments
December 17, 2021
SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and...
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Year End Review and Outlook
December 09, 2021
SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma Research and Vision
November 30, 2021
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
November 08, 2021
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
October 27, 2021
SAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
October 15, 2021
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 12, 2021
SAN FRANCISCO, CA / ACCESSWIRE / October 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") would like to update investors on its progress. The Company is in the...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
September 13, 2021
SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company")...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
August 23, 2021
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
August 19, 2021
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
July 20, 2021
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward....
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
June 30, 2021
SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
June 15, 2021
SAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
June 09, 2021
SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') is releasing a White Paper outlining 5 innovative ways to improve patient...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
May 18, 2021
SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
May 12, 2021
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
May 07, 2021
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
April 21, 2021
SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is moving ahead with advancing its efforts with Ribera Solutions' Conect2Med...
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
